Latest Articles and Analysis

US monkeypox response: 31% of cases among Black persons, vaccine distribution equity concerns persist.

85,000+ fake HIV medication bottles distributed through counterfeiting rings endanger patient safety.

ADAP Advocacy Association Fireside Chats resume with discussions on utilization management and EHE progress.

Conference examines HIV and methamphetamine use intersection among MSM and transgender communities.

2020 CDC HIV surveillance reveals COVID-19's impact on HIV prevention and testing with decreased diagnoses and increased deaths.

Health misinformation undermines vaccine confidence, perpetuates stigma, and drives poor policy decisions.

CANN roundtable examines COVID-19 impacts on public health advocacy, Medicaid expansion, and HIV programs.

Pediatric hepatitis investigations lack typical viruses but show adenovirus and potential COVID-19 involvement.

STI and HCV rates rise despite reduced screening, reflecting chronic public health underfunding.

Biden's SOTU addresses harm reduction, endorses MAT Act; limited HIV-specific programming focus.

Access Health Louisiana uses animated series and radio to educate communities on HIV, HCV, and public health.

CDC updates STI treatment guidelines; ACIP recommends universal adult HBV vaccination and HPV catch-up.

Payers restrict HCV treatment through utilization management; patient assistance programs fill the critical gap.

Global Fund report shows COVID-19 reduced HIV/HCV program efficacy while South Africa tripled ART coverage.

COVID-19 strains public health efforts addressing HIV outbreaks, diverting resources from the domestic epidemic.

Post-PHE planning for Medicaid redetermination: extended timelines and navigator support for safety net care.

Nobel laureate's HCV vaccine development targeting 2029 offers hope alongside access equity challenges.

Explores the personal toll of patient advocacy, examining burnout and the need to support advocates.

WHO 2030 HCV elimination goal at risk; only 5 of 110 countries on track as COVID-19 disrupts progress.

CANN roundtable discusses pandemic's impacts on HIV, HCV, STI, and SUD programs and funding weaknesses.